profit from every CHF 100 of sales.
CHF 0CHF 100
Idorsia
CHF 4.15+2.37% today
-0.1% in 1 year
1-year low CHF 2.931-year high CHF 6.89
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Idorsia sold, what it kept, and what it did with the cash.
Sales went from CHF 97.1 million in 2022 to CHF 221 million in 2025, with -CHF 112 million of profit last year.
SalesProfit
Idorsia vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Idorsia | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Idorsia's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 97 | 152 | 113 | 221 | |
| 91 | 145 | 77 | 200 | |
| -803 | -543 | -337 | -116 | |
| -783 | -255 | -226 | -45 | |
| -828 | -298 | -264 | -112 | |
| -4.67 | -1.67 | -1.45 | -0.52 | |
| 93.5% | 95.3% | 68.1% | 90.5% | |
| -826.9% | -356.4% | -299.8% | -52.8% | |
| -852.6% | -195.5% | -234.4% | -50.6% |
Balance sheet
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 904 | 500 | 506 | 466 |
| Cash | 146 | 145 | 106 | 87 |
| Total debt | 1,227 | 1,204 | 1,257 | 1,267 |
| Total liabilities | 1,565 | 1,469 | 1,718 | 1,603 |
| -661 | -969 | -1,212 | -1,137 | |
| 177 | 178 | 182 | 215 | |
| -120.5% | -99.0% | -466.6% | -41.2% | |
| 125.3% | 30.8% | 21.8% | 9.8% |
Cash flow
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -859 | -629 | -370 | -153 | |
| 27 | 9 | 18 | 14 | |
| -886 | -639 | -388 | -167 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | – | |
| 26 | 23 | 12 | 6 |
Valuation
- –
- –
- –
- -1.0×
- 5.1×
- –
- –
- -14.9%
- -10.0%
- –
Profitability
- 90.5%
- -52.8%
- -50.6%
- –
- -41.2%
- -181.8%
- –
- –
- –
- –
Growth
- +31.5%
- –
- –
- –
- +6.6%
Financial health
- –
- -1.11
- –
- -1.5×
- 1.39
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 11%of 948
Bottom 7%of 871
Top 19%of 868
Bottom 7%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
32No pass
Benjamin Graham
17No pass
Philip Fisher
50No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
34No pass
Terry Smith
44No pass
Questions about Idorsia
Is Idorsia a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Idorsia AI analysis
What does Idorsia do?
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. It is in Biotechnology, based in Allschwil, Switzerland, with 424 employees.
Is Idorsia stock halal?
No. Idorsia does not pass our halal screen: its debt is 113% of its market value, at or above the 33% limit. How we check
How has Idorsia stock done over the past year?
Down 0.1% over the past twelve months, to CHF 4.15. It traded between CHF 2.93 and CHF 6.89 and is 39.7% below its high.
Who are Idorsia's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Idorsia's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.